Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:DTIL NASDAQ:PDLI NASDAQ:TBIO NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$6.83-3.3%$4.45$1.38▼$18.74$187.26M1.51735,776 shs1.62 million shsDTILPrecision BioSciences$4.64+4.3%$4.80$3.61▼$11.09$51.46M1.43227,308 shs179,848 shsPDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/ATBIOTelesis Bio$0.02-91.9%$0.11$0.01▼$6.17$44K0.966,682 shs663 shsVYGRVoyager Therapeutics$3.43-1.7%$3.20$2.65▼$9.55$189.82M0.85487,510 shs491,566 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus0.00%+19.06%+50.21%+296.63%-54.74%DTILPrecision BioSciences0.00%+1.71%-9.18%-0.22%-56.07%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%TBIOTelesis Bio0.00%0.00%+500.00%-60.00%-91.83%VYGRVoyager Therapeutics0.00%+6.40%+5.76%+9.40%-60.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus4.3175 of 5 stars3.24.00.04.62.51.70.6DTILPrecision BioSciences4.2893 of 5 stars3.51.00.04.63.11.71.3PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ATBIOTelesis BioN/AN/AN/AN/AN/AN/AN/AN/AVYGRVoyager Therapeutics3.978 of 5 stars3.62.00.04.62.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.33Hold$14.00104.98% UpsideDTILPrecision BioSciences 3.00Buy$47.00912.93% UpsidePDLIPDL BioPharma 0.00N/AN/AN/ATBIOTelesis Bio 0.00N/AN/AN/AVYGRVoyager Therapeutics 3.13Buy$13.39290.38% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, AGEN, PDLI, TBIO, and VYGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$99.52M1.88N/AN/A($13.06) per share-0.52DTILPrecision BioSciences$68.70M0.75N/AN/A$6.87 per share0.68PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/ATBIOTelesis Bio$225.09M0.00N/AN/A$0.14 per share0.17VYGRVoyager Therapeutics$80M2.37N/AN/A$5.49 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)PDLIPDL BioPharmaN/A$0.1913.00∞N/AN/AN/AN/AN/ATBIOTelesis Bio-$47.72M-$28.20N/A∞N/A-336.59%N/A-61.89%8/5/2025 (Estimated)VYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)Latest DTIL, AGEN, PDLI, TBIO, and VYGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DTILPrecision BioSciences-$0.09N/AN/AN/A$6.27 millionN/A8/5/2025Q2 2025VYGRVoyager Therapeutics-$0.48N/AN/AN/A$9.50 millionN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/ATBIOTelesis BioN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.110.11DTILPrecision BioSciences0.456.626.62PDLIPDL BioPharmaN/AN/AN/ATBIOTelesis BioN/A1.231.06VYGRVoyager TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%DTILPrecision BioSciences37.99%PDLIPDL BioPharmaN/ATBIOTelesis Bio37.63%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%DTILPrecision BioSciences4.00%PDLIPDL BioPharma11.70%TBIOTelesis Bio24.50%VYGRVoyager Therapeutics4.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million25.91 millionOptionableDTILPrecision BioSciences20011.09 million10.64 millionNo DataPDLIPDL BioPharma109N/AN/AOptionableTBIOTelesis Bio2001.80 million1.36 millionOptionableVYGRVoyager Therapeutics10055.34 million52.83 millionOptionableDTIL, AGEN, PDLI, TBIO, and VYGR HeadlinesRecent News About These CompaniesEmbark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More4 hours ago | prestigeonline.comPVoyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek4 hours ago | fandomwire.comFUK awards AirTanker network node upgrade for VoyagerJuly 11 at 10:28 AM | janes.comJVoyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current TechnologyJuly 10, 2025 | msn.comBrokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39July 8, 2025 | americanbankingnews.comRNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'July 7, 2025 | itv.comIAtlas Announces New Canadian Arctic Expedition Aboard World VoyagerJuly 6, 2025 | cruiseindustrynews.comCWith Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-WalletsJuly 5, 2025 | travelmole.comTVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesJuly 5, 2025 | marketbeat.comAnt International launches Alipay+ Voyager, an AI-powered travel assistant inside e-walletsJuly 3, 2025 | walastech.comWVYGR Voyager Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMajor Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With PaintJune 20, 2025 | theaviationist.comTProtesters Vandalize RAF Voyager Tankers In Palestine ProtestJune 20, 2025 | aviationweek.comAVoyager Technologies Soars with IPO SuccessJune 14, 2025 | devdiscourse.comDSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12, 2025 | devdiscourse.comDVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12, 2025 | msn.comVoyager soars 82% on first day of trading as defense tech boomsJune 12, 2025 | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11, 2025 | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11, 2025 | marketwatch.comVoyager Technologies Shares Soar In Market DebutJune 11, 2025 | news.crunchbase.comNSpace tech firm Voyager valued at $3.8 billion as shares surge in NYSE debutJune 11, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsDTIL, AGEN, PDLI, TBIO, and VYGR Company DescriptionsAgenus NASDAQ:AGEN$6.83 -0.23 (-3.26%) Closing price 04:00 PM EasternExtended Trading$6.74 -0.09 (-1.32%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Precision BioSciences NASDAQ:DTIL$4.64 +0.19 (+4.27%) Closing price 04:00 PM EasternExtended Trading$4.57 -0.07 (-1.51%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.PDL BioPharma NASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.Telesis Bio NASDAQ:TBIO$0.02 -0.28 (-91.90%) As of 02:53 PM EasternTelesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Voyager Therapeutics NASDAQ:VYGR$3.43 -0.06 (-1.72%) Closing price 04:00 PM EasternExtended Trading$3.49 +0.06 (+1.72%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
